# Novel Drug Approvals at FDA

## Novel Drug Approvals for 2023

39. **Rezzayo**: Approved on March 22, 2023, Rezzayo, containing rezafungin, is indicated for the treatment of candidemia and invasive candidiasis.

40. **Litfulo**: Litfulo, with the active ingredient ritlecitin

ib, was approved on June 23, 2023, for the treatment of severely patchy hair loss.

41. **Rystiggo**: Approved on June 26, 2023, Rystiggo, containing rozanolixizumab-noli, is used for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive.

42. **Ngenla**: Ngenla, with the active ingredient somatrogon-ghla, was approved on June 27, 2023, for the treatment of growth failure due to inadequate secretion of endogenous growth hormone.

43. **Inpefa**: Approved on May 26, 2023, Inpefa, containing sotagliflozin, is indicated for the treatment of heart failure.

44. **Filspari**: Filspari, with the active ingredient sparsentan, was approved on February 17, 2023, to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression.

45. **Xacduro**: Approved on May 23, 2023, Xacduro, containing sulbactam and durlobactam, is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
